Your session is about to expire
← Back to Search
Adoptive Cell Transfer + Interleukin 2 for Cancer
Study Summary
This trial will test whether taking tumor cells and growing them in the lab to create more tumor-fighting cells, which are then put back into the patient, can help fight cancer when the patient's immune system is suppressed.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My head or neck cancer has returned or spread.I have a condition that significantly weakens my immune system.It has been over four weeks since my last systemic therapy.I need medication to suppress my immune system, including steroids.I have up to 3 brain metastases that are stable and treated if needed.I am pregnant or breastfeeding.You are expected to live for at least 3 more months.I have undergone cell transfer therapy with intense chemotherapy.I have had heart surgery or symptoms due to poor blood flow.You do not have HIV antibodies in your blood.I have infections due to a weakened immune system.My melanoma cannot be surgically removed and is in stage III or IV.My organs and bone marrow are working well.You do not have markers for hepatitis B or hepatitis C in your blood.My cancer has worsened after treatment and cannot be cured with known therapies.I am fully active or can carry out light work.It has been over 6 weeks since my last anti-CTLA4 antibody treatment.My condition hasn't improved or has worsened despite treatment.I do not have active infections, bleeding disorders, or serious heart, lung, or immune diseases.My condition worsened after at least one treatment.I have a serious heart rhythm problem.I have been diagnosed with head and neck cancer or melanoma that can be measured.
- Group 1: melanoma
- Group 2: head and neck cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned utilizing Autologous Tumor Infiltrating Lymphocytes?
"The predicted safety of Autologous Tumor Infiltrating Lymphocytes is estimated to be 1 due to its position in Phase 1 trials. This indicates that there has been limited clinical data demonstrating the efficacy and safety of this medication."
Is participation in this trial still being accepted?
"The clinical trial in question, posted on October 7th 2020 and last updated November 1st 2021, is no longer recruiting volunteers. Nevertheless, there are 2136 other medical studies which are currently open to participants."
Share this study with friends
Copy Link
Messenger